Videos
Ivantis was founded in 2007 by two coronary stent inventors to develop “the only minimally invasive microstent for glaucoma that dilates and scaffolds Schlemm’s canal.”…
Read MoreResults from a Phase I/Phase II study of EV06 ophthalmic solution for the treatment of presbyopia show “it works to restore bilateral near vision. It…
Read MoreThe Raindrop Near Vision Inlay for the treatment of presbyopia boasts a 2-mm diameter, 80% water composition, the same refractive index as the natural cornea,…
Read MoreBarry Cheskin, CEO, president and co-founder of PowerVision, provides details on his company’s new partnership with Alcon. Video Highlights: 00:30 – Details on Alcon deal…
Read MoreAllergan purchased AqueSys (developer of the Xen Gel Stent) in a $20 million deal earlier this year. “Just a few years ago, the energy and…
Read MoreRefocus Group’s goal, according to CEO Mike Judy, is to become the preferred surgical alternative for the treatment of presbyopia. The VisAbility Implant System (VIS)…
Read MoreThe “What’s the Future@OIS” session at OIS@ASCRS 2016 showcased five novel innovations in ophthalmology that are difficult to place into any existing categories of ophthalmic…
Read MoreThe profoundly blind form mental images of their surroundings from a variety of stimuli – touch, echo location, the their tip of cane or guide…
Read MorePresbyopia Therapies LLC is developing an eyedrop that can correct presbyopia for six hours or so before it wears off, co-founder Jim McCollum told OIS@ASCRS…
Read MoreSUBSCRIBE TO OIS NEWS
Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.
We respect your privacy and promise to never send you spam.